The current study was undertaken to develop the new bioanalytical method and validation for determining Clarithromycin by LC-MS Method and as well as to conduct in vivo studies. Princeton octadecyl silane column (10 cm x 4.6 mm id, 5µm) used as adsorbent and cyanomethane: 0.5 % Methanoic acid
was treated as the eluent for the separation of the analyte from the biological luid in an isocratic mode having the ratio 60:40 % v/v and 0.5 ml/min as low rate, and injection volume was set as 20 µl. APCI and the mass detected of Clarithromycin and Azithromycin (act as internal standard) was detected at 748.45 and 749.70, respectively. Developed bioanalytical methods have been used to quantify the Pharmacokinetic parameters like C max , T max , AUC0t & AUC0-∞, K eli , and t 1/2 studied and the values for reference formulation (3.382µg/ml, 7.333 h, 114.429µg.h/ml, 131.435µg .h/ml, 0.031 h −1 , and 23.397h respectively) and the test formulation (3.847 µg/ml, 7.417 h, 132.318 µg.h/ml, 151.388 µg.h/ml, 0 .031 h −1 , and 23.187 h, respectively) were compared and found to be bioequivalent. Based on our study, the test formulation of Clarithromycin modi ied-release formulation containing 500 mg of Clarithromycin is Bioequivalent to that of the reference. Compare to our method (LC-MS) is simple, sensitive, precise as well as comparable with the reference formulation of the modi ied release product of clarithromycin 500 mg.
INTRODUCTION
Clarithromycin is a good example of broad-spectrum macrolide antibacterial drugs (Langtry and Brogden, 1997; Jelić and Antolović, 2016) , and the chemical structure of Clarithromycin is obtained from erythromycin-A (Dinos et al., 2003) . It is used to treat a wide variety of bacterial infections, and it can be taken orally. Clarithromycin is also prescribed along with anti-ulcer drugs as a combination. Clarithromycin is available as immediaterelease formulation as well as modi ied-release formulations. Whenever they want to release the product in the market, the concerned company should study bioequivalence studies. Bioequivalence studies (BE) (Yu and Li, 2014) are conducted to investigate the pharmacokinetic parameters of two pharmaceutical formulations of the same drug and to demonstrate the equivalence of their pharmacokinetic parameters. BE studies are accessed via whole blood/plasma/serum /urine data using the following parameters: AUC or the cumulative amount of drug excreted in the urine, C max , or the rate of drug excretion in urine and T max . The present study was undertaken to establish the new method for the quanti ication of Clarithromycin in blood plasma and validated the developed method as per the US FDA guidelines as well as after validation to perform in vivo studies (Alkhalidi et al., 2008; Samiullah et al., 2017) to prove the equivalence of test Clarithromycin concerning the reference Clarithromycin modi ied release dosage form.
Eluent and chemicals:
Cyanomethane and Methanoic acid HPLC quality obtained from Merck, Ammonium acetate was procured from SD ine chem and HPLC quality aqua obtained from a Milli-Q Reverse Osmosis system. The working standard of Clarithromycin obtained from Neopharma, Abu Dhabi.
MATERIALS AND METHODS

Instruments
To perform the bioanalytical study of Clarithromycin, Shimadzu 2010A LC-MS has been used.
Separation conditions
LC Conditions
Stationary phase: Princeton 10 cm octadecyl silane column (with 4.6 mm, i.e., 5 µm) was used and Cyanomethane: 0.5 % Methanoic acid, considered as eluent to separate analyte in an isocratic mode having the ratio of 60:40 % v/v respectively. The low rate of the eluent was ixed:0.5 ml/min, and the volume of Injection in the system was 20 µl/L using the Autoinjector.
MS Conditions
Interface: APCI and SIM mode having positive polarity with ambient probe temperature, CDL & Block Temperature 250º C & 200º C, respectively. The mass detected of Clarithromycin and Azithromycin (act as internal standard) was detected at 748.45 and 749.70, respectively. The entire analysis was conducted at ambient conditions.
Preparation of Clarithromycin standard stock solution
Constituted 1 mg/ml solution by weighing 100mg of Clarithromycin and dissolved in 100ml of Cyanomethane. Labeled the container and stored below 8 • C.
Standard solution for Calibration Curve
Constituted 10 ml of each of 0.3, 0.5, 1, 2, 3, 4, 5, and 6 µg/ml of standard solutions for calibration curve obtained from Clarithromycin standard stock solutions by using eluent and inally stored at -20±2 ºC until analysis.
Standard solution for Quality Control
Constituted 10 ml each of 0.3, 3, and 6 µg/ml of Clarithromycin standard solutions for quality control obtained from Clarithromycin standard stock solution and eluent and stored at -20±2ºC until analysis Figures 1, 2 and 3. 
Preparation of stock and Calibration curve samples
Constituted 10.0 ml each of 0.6, 1, 2, 4, 6, 8, 10, and 12 µg/ml of clarithromycin calibration curve samples using clarithromycin standard stock solution with blank human plasma. After the dilution calibration curve samples are transferred into different 2.0 ml centrifuge tubes and stored at -70±2 ºC until processing.
Preparation of Quality Control Samples
Constituted 10.0 ml each of 0.6, 6.0, and 12.0 µg/ml of Clarithromycin Calibration curve samples from of Clarithromycin standard stock solution (0.5 ml) and made up the volume with blank plasma, transfer into different 2.0 ml centrifuge tubes and stored at-70±2 ºC until processing.
Preparation of plasma samples
Plasma samples were drawn from the deep freezer and kept in the ambient temperature and allowed to thaw. 0.5 ml of the plasma sample pipetted into a 2.0 ml centrifuge tubes with this 50 µl of azithromycin solution (100 µg/ml) and 1.0 ml of the cyanomethane (as precipitating agent) was added. The resulting solution was vortexed for 5 minutes and centrifuged at 4,000 rpm for 10 min. Supernatant liquid from the above solutions separated and used for the analysis.
Order of Analysis
Injected 10 µl of each sample in the following order: The standard solutions, linearity samples, quality control samples, and plasma sample solutions injected with the above separation conditions and recorded the chromatograms. The quanti ication achieved as per the guidelines.
Validation Studies
Accuracy and Precision
Accuracy and precision of the method achieved as per the USFDA guidelines. Precision studies were undertaken in three levels (Low QC, Middle QC, and High QC) at nine times and three different occasions. The results are tabulated in Table 1 .
Selectivity
Blank plasma samples were harvested from six different volunteers and analyzed for selectivity. The chromatograms were obtained after the analysis and compared with the standard chromatograms for the interference studies. No interferences found in the chromatograms.
Linearity and Range
0.3, 0.5, 1, 2, 3, 4, 5, and 6 µg/ml of Clarithromycin analyzed, and the peak areas and response factors were determined as per the guidelines. Stability Studies, Limit of Detection, Limit of Quanti ication, Robustness, and ruggedness have been studied as per the USFDA guidelines given in Table 2 .
System suitability
The results of column ef iciency, peak symmetry factor, resolution factor, and capacity factor for the standard Clarithromycin solutions were computed in Table 3 .
In-Vivo Study
In vivo study performed by recruiting the healthy human volunteers by using crossover study with randomization, single-dose of Clarithromycin under fasting conditions. After recruiting the volun- teers, 15 blood samples were harvested at dosing. Blood samples were harvested through an indwelling cannula placed in a forearm vein. The pre-dose blood sample was harvested within one hour before dosing, and post-dose samples were collected within 2-minutes of the scheduled time. The blood samples were collected in vacutainers containing sodium citrate as the anticoagulant. Plasma separated and divided into two portions while storing the containers labeled and stored at -70 ºC till analysis and study are conducted as per the prior approval from the institutional ethics committee (JSSCP/HEC/LOA/ 077).
Study Design
After a single oral dose of the Clarithromycin in 24 (+2 standby) healthy male human volunteers in a randomized, two-way, two-period, crossover design. In each dosing session, volunteers received either the Reference or Test formulation of respective formulation as a single-dose, only on the study day, as per the randomization code at a ixed time.
Blood Sampling Schedule
Blood samples were obtained from the volunteer at speci ic time points from 0 (before drug administration), 30, 60, 90, 120, 150, 180, 240, 300, 360, 480, 720, 1440, 2160, 2880, 3600 , and 4320 min-utes with 10 days washout period between two periods.
RESULTS AND DISCUSSION
Validation of the developed method as per USFDA guidelines
Selectivity and Sensitivity, Accuracy, and Precision studies
Selectivity and sensitivity, accuracy, and precision studies observed as per the USFDA guidelines. All the values fall within the criteria. Accuracy studies details have been present in Table 1 Linearity Studies Linearity and range studies Figure 4 have been studied by using different concentrations of standard solutions of the study drugs prepared and analyzed along with Azithromycin as an internal standard. After the analysis, the response factor evaluated. As per the USFDA guidelines, the linearity and range calculated, and it has shown the R 2 value within the range mentioned in Table 2 .
Stability Studies
Stability studies of plasma samples spiked with Clarithromycin subjected to three freeze-thaw cycles, Short term stability at room temperature for 3
Figure 4: Calibration curve of clarithromycin
hours, and long term stability at -70 ºC over three weeks. The stability studies data presented in Table 3 No degradation was found in both short term and long term stability studies.
System suitability
The parameters, namely the Asymmetric factor, resolution factor, and theoretical plate for the standard solutions calculated. The determination of the LOD and LOQ computed based on the signal-tonoise ratio. The data demonstrates that the developed methods have adequate sensitivity. The values obtained demonstrated the suitability of the system for the analysis of Clarithromycin in plasma in Table 4 .
Ruggedness and Robustness
Robustness and ruggedness studies established as per the US-FDA guidelines by changing the pH, low rate, and it fell within the prescribed criteria.
Pharmacokinetics Data
Pharmacokinetic parameters such as Peak plasma concentration (C max ), Time to peak concentration (T max ), Area under the plasma concentration-time curve (AUC 0−t & AUC 0−∞ ), elimination rate constant (K eli ), Elimination half-life (t 1/2 ) calculated separately and the blood level data of the Reference product and the Test product compared.
Volunteers have taken the dosage forms by orally after the administration of the Reference formulation, and the test formulation in the fasting state exhibited measurable Clarithromycin blood levels in all the volunteers from 0.50 hr. Onwards Based on the Pharmacokinetic data namely, AUC 0−t , T max , C max , K eli , Half-life and AUC 0−inf of the reference and the test formulations and their statistical analysis concluded that the Test formulation of Clarithromycin containing 500 mg of clarithromycin is Bioequivalent to that of Reference formulation and which is exhibited in Table 5 .
The improved validated analytical method represents an accurate, precise, linear, selective, and sensitive method for the quanti ication of Clarithromycin. Based on the Pharmacokinetic data namely, C max , T max , AUC0-t & AUC0-∞, K eli , and t 1/2 studied and the values for reference formulation (3.382µg/ml, 7.333 h, 114.429µg.h/ml, 131.435µg .h/ml, 0.031 h −1 , and 23.397h respectively) and the test formulation (3.847 µg/ml, 7.417 h, 132.318 µg.h/ml, 151.388 µg.h/ml, 0 .031 h −1 , and 23.187 h, respectively) were compared and found to be bioequivalent.
